^
BIOMARKER:
TMB-H
i
Other names: TMB | Tumor Mutational Burden
Related biomarkers:
›
TMB-H
|
Penile Cancer
|
TMB-H
|
Penile Cancer
|
pembrolizumab Sensitive: A2 - Guideline
NCCN - 4 weeks
|
pembrolizumab Sensitive: A2 - Guideline
NCCN - 4 weeks
|
TMB-H
|
Solid Tumor
|
TMB-H
|
Solid Tumor
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
TMB-H
|
Peritoneal Cancer
|
TMB-H
|
Peritoneal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Gastric Cancer
|
TMB-H
|
Gastric Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Testicular Seminoma
|
TMB-H
|
Testicular Seminoma
|
TIP Sensitive: A2 - Guideline
|
TIP Sensitive: A2 - Guideline
|
TMB-H
|
Sarcoma
|
TMB-H
|
Sarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Hurthle Cell Carcinoma
|
TMB-H
|
Thyroid Gland Hurthle Cell Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Chordoma
|
TMB-H
|
Chordoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Germ Cell Tumors
|
TMB-H
|
Germ Cell Tumors
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Follicular Carcinoma
|
TMB-H
|
Thyroid Gland Follicular Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Medullary Carcinoma
|
TMB-H
|
Thyroid Gland Medullary Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Endometrial Cancer
|
TMB-H
|
Endometrial Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Cervical Cancer
|
TMB-H
|
Cervical Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Papillary Carcinoma
|
TMB-H
|
Thyroid Gland Papillary Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
TMB-H
|
Breast Cancer
|
TMB-H
|
Breast Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
TMB-H
|
Ewing Sarcoma
|
TMB-H
|
Ewing Sarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Osteosarcoma
|
TMB-H
|
Osteosarcoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Thyroid Gland Anaplastic Carcinoma
|
TMB-H
|
Thyroid Gland Anaplastic Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Gastroesophageal Junction Adenocarcinoma
|
TMB-H
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Esophageal Cancer
|
TMB-H
|
Esophageal Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Ovarian Cancer
|
TMB-H
|
Ovarian Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Fallopian Tube Cancer
|
TMB-H
|
Fallopian Tube Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Neuroendocrine Tumor
|
TMB-H
|
Neuroendocrine Tumor
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Testicular Cancer
|
TMB-H
|
Testicular Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Vulvar Cancer
|
TMB-H
|
Vulvar Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Prostate Cancer
|
TMB-H
|
Prostate Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
Nasopharyngeal Carcinoma
|
TMB-H
|
Nasopharyngeal Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
atezolizumab Sensitive: B - Late Trials
|
atezolizumab Sensitive: B - Late Trials
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
atezolizumab + cobimetinib Sensitive: B - Late Trials
|
atezolizumab + cobimetinib Sensitive: B - Late Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials
|
vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials
|
TMB-H
|
Pancreatic Cancer
|
TMB-H
|
Pancreatic Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
ipilimumab Sensitive: B - Late Trials
|
ipilimumab Sensitive: B - Late Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
TMB-H
|
Small Cell Lung Cancer
|
TMB-H
|
Small Cell Lung Cancer
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
TMB-H
|
Small Cell Lung Cancer
|
TMB-H
|
Small Cell Lung Cancer
|
nivolumab Sensitive: B - Late Trials
|
nivolumab Sensitive: B - Late Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD1 inhibitor Sensitive: B - Late Trials
|
TMB-H
|
Pancreatic Cancer
|
TMB-H
|
Pancreatic Cancer
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD1 inhibitor Sensitive: B - Late Trials
|
TMB-H
|
Triple Negative Breast Cancer
|
TMB-H
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
Squamous Cell Skin Cancer
|
TMB-H
|
Squamous Cell Skin Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
CRC
|
TMB-H
|
CRC
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
Bladder Cancer
|
TMB-H
|
Bladder Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
Pancreatic Adenocarcinoma
|
TMB-H
|
Pancreatic Adenocarcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
TMB-H
|
Gastric Cancer
|
TMB-H
|
Gastric Cancer
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
toripalimab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
Prostate Cancer
|
TMB-H
|
Prostate Cancer
|
nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
|
nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
Prostate Cancer
|
TMB-H
|
Prostate Cancer
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
Solid Tumor
|
TMB-H
|
Solid Tumor
|
nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
|
nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
Solid Tumor
|
TMB-H
|
Solid Tumor
|
atezolizumab Sensitive: C2 – Inclusion Criteria
|
atezolizumab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
Gastric Cancer
|
TMB-H
|
Gastric Cancer
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
sintilimab Sensitive: C2 – Inclusion Criteria
NPJ Precis Oncol - 1 week
|
sintilimab Sensitive: C2 – Inclusion Criteria
NPJ Precis Oncol - 1 week
|
TMB-H
|
Solid Tumor
|
TMB-H
|
Solid Tumor
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
sintilimab Sensitive: C2 – Inclusion Criteria
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
atezolizumab Sensitive: C3 – Early Trials
|
atezolizumab Sensitive: C3 – Early Trials
|
TMB-H
|
Neuroendocrine Tumor
|
TMB-H
|
Neuroendocrine Tumor
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
TMB-H
|
Triple Negative Breast Cancer
|
TMB-H
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: C3 – Early Trials
|
atezolizumab Sensitive: C3 – Early Trials
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
TMB-H
|
Solid Tumor
|
TMB-H
|
Solid Tumor
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
SCCHN
|
TMB-H
|
SCCHN
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TMB-H
|
MDS
|
TMB-H
|
MDS
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
Prostate Cancer
|
TMB-H
|
Prostate Cancer
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TMB-H
|
CRC
|
TMB-H
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
Prostate Cancer
|
TMB-H
|
Prostate Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
BCC
|
TMB-H
|
BCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
GBM
|
TMB-H
|
GBM
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
Bladder Cancer
|
TMB-H
|
Bladder Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
Breast Cancer
|
TMB-H
|
Breast Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
TMB-H
|
Endometrial Cancer
|
TMB-H
|
Endometrial Cancer
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
TMB-H
|
NSCLC
|
TMB-H
|
NSCLC
|
PF-06801591 Sensitive: C3 – Early Trials
|
PF-06801591 Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
durvalumab + ABSK091 Sensitive: C3 – Early Trials
|
durvalumab + ABSK091 Sensitive: C3 – Early Trials
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
atezolizumab Sensitive: C3 – Early Trials
|
atezolizumab Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
avelumab Sensitive: C3 – Early Trials
|
avelumab Sensitive: C3 – Early Trials
|
TMB-H
|
Esophageal Cancer
|
TMB-H
|
Esophageal Cancer
|
camrelizumab Sensitive: C3 – Early Trials
|
camrelizumab Sensitive: C3 – Early Trials
|
TMB-H
|
Urothelial Cancer
|
TMB-H
|
Urothelial Cancer
|
ABSK091 Sensitive: C3 – Early Trials
|
ABSK091 Sensitive: C3 – Early Trials
|
TMB-H
|
Thyroid Gland Carcinoma
|
TMB-H
|
Thyroid Gland Carcinoma
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
TMB-H
|
Thyroid Gland Anaplastic Carcinoma
|
TMB-H
|
Thyroid Gland Anaplastic Carcinoma
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
TMB-H
|
CRC
|
TMB-H
|
CRC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
TMB-H
|
Gastric Cancer
|
TMB-H
|
Gastric Cancer
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
